The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...